Sunday, 24 June 2012

Side Effects of Deflazacort

Welcome To Plenus Pharmaceuticals (P) Ltd 
Deflazacort

Plenus Pharmaceuticals is built on its meaning of completeness in pharmaceutical field through our quality healthcare service that leads to healthy life everywhere. It is complete healthcare in every aspect where there is no compromise with quality of products, ensuring full satisfaction to concerned entities.

Skin Lesions: Acne is a term used to describe small, fluid- or pus-filled skin lesions that develop due to inflammation of the oil-producing glands in the skin. Acne may be embarrassing and may be tender or painful to the touch. Patients who develop stretch marks may notice long, thin lines of discolored skin across their thighs, stomach or breasts.

Recurrent Infections: Corticosteroids, such as deflazacort, interfere with the normal function of a patient's immune system. Patients may have a more difficult time fighting off infection while receiving treatment with this medication. Patients may develop recurrent infections, such as the flu, a cold or pneumonia, or they may find it takes longer for their skin to heal following injury.

Muscle or Bone Weakness : Treatment with deflazacort may cause bone or muscle wasting, which leads to decreased muscle strength and bone weakness in affected patients. Excessive bone loss may result in the development of osteoporosis, a bone disease that makes a patient's bones more susceptible to fractures.

Cushing's syndrome: Patients who use this medication excessively or for a prolonged period of time may develop a condition called Cushing's syndrome. Persistent exposure to corticosteroids elevates the levels of cortical, a naturally occurring hormone, resulting in Cushing's syndrome. Symptoms associated with this condition include severe fatigue, increased blood sugar, bruising, back or body aches, weakness, elevated blood pressure or upper body weight gain.

Deflazacort is important for children to receive frequent physical checkups to ensure they meet appropriate developmental and growth milestones. The frequency of these side-effects is unknown abnormal laboratory test results, acne, adrenal problems, amenorrhea, appetite gain, blood problems. People who experience severe anaphylactic or allergic reactions or have certain types of inflammatory conditions, such as arthritis or asthma, may benefit from treatment with deflazacort.


Keywords

Contact Us-
Plenus Pharmaceuticals Private Limited
PLENUS BUILDING
SHIV VIHAR, NEAR LAL MANDIR,
ARYA NAGAR JWALAPUR,
HARIDWAR. (U.K.) 249407
Mobile: 09737475726













Friday, 15 June 2012

Informations of Deflazacort


Welcome To Plenus Pharmaceuticals (P) Ltd 
Informations of Deflazacort

 Plenus Pharmaceuticals is built on its meaning of completeness in pharmaceutical field through our quality healthcare service that leads to healthy life everywhere. It is complete healthcare in every aspect where there is no compromise with quality of products, ensuring full satisfaction to concerned entities.

Deflazacort is a prodrug. Its potency is around 70–90% that of prednisone. Steroids form an important component of dermatological therapy and are used since very long time for different conditions in different forms. Though very few molecules are used since very long time, the side effect associated with this group of drugs are almost always there. Recently a new molecule deflazacort has been introduced into Indian market, is a glucocorticoid and a derivative of old molecule prednisolone. Deflazacort is a glucocorticoid. Its anti-inflammatory and immunosuppressive effects are used in treating various diseases and are comparable to other anti-inflammatory steroids. Clinical studies have indicated that the average potency ratio of deflazacort to prednisolone is 0.69-0.89 and 6 mg of deflazacort is equivalent to 5 mg of prednisolone.

Deflazacort is a glucocorticoid derived from prednisolone and 6 mg of deflazacort it has approximately the same anti-inflammatory potency as 5 mg prednisolone or prednisone. Doses vary widely in different diseases and different patients. In more serious and life-threatening conditions, high doses of deflazacort may need to be given. When deflazacort is used for long term in relatively benign chronic diseases, the maintenance dose should be kept as low as possible. Dosage may need to be increased during periods of stress or during exacerbation of illness. The dosage should be individually titrated according to diagnosis, severity of disease and patient response and tolerance. The lowest dose that will produce an acceptable response should be used. The dose of deflazacort should be carefully monitored and adjusted to the minimum effective dose.


Keywords

Contact Us-

Plenus Pharmaceuticals Private Limited
PLENUS BUILDING
SHIV VIHAR, NEAR LAL MANDIR,
ARYA NAGAR JWALAPUR,
HARIDWAR. (U.K.) 249407
Mobile: 09737475726